DID YOU KNOW?

The Reichstag Building in the heart of Berlin's city centre was destroyed in 1933 by a huge fire. It was renovated and renewed in 1999 with an iconic glass dome at the very top of the building.

The dome offers visitors a spectacular view of the surrounding Berlin cityscape.

photo: franknuernberger.de

ECCO 15 and 34th ESMO Multidisciplinary Congress
Berlin, 20 - 24 September 2009

This month's ECCO 15 - ESMO 34 Congress Update Service brings you important information about Late-Breaking Abstract Submission, a pick of programme highlights and updates, Educational Symposia synopses and much more!

For an informative update on Influenza A (H1N1) from the Congress Secretariat click here

Programme Highlights

Specially selected ECCO 15 - ESMO 34 Programme Highlights for this month's Congress Update Service include:

Educational Symposia

Teaching Lectures

EACR Special Conference on Inflammation and Cancer

Late-Breaking Abstracts

To capture abstracts with ground-breaking and unique data, Late-Breaking Abstract Submission opens online: 22 July - 05 August 2009.

Click on 'MORE >' below for further information.

Satellite Symposia

ECCO 15 - ESMO 34 Satellite Symposia provide an essential platform to further update all participants on cutting edge scientific information, developments, treatment modalities and strategies.

Click on 'MORE >' below to discover the series of exciting ECCO 15 - ESMO 34 Satellite Symposia.

More >

More >

More >

REGISTER NOW >
Programme Highlights

Educational Symposia

Teaching Lectures

EACR Special Conference on Inflammation and Cancer

For a flavour of what’s in store at the ECCO 15 - ESMO 34 Educational Symposia series we have selected the following three highlights:

• All you wanted to know about cancer stem cells but were afraid to ask Tuesday 22 September 2009, 17:00 - 18:00
  Chaired by M. Alison (UK) this session will cover the topic of cancer stem cells - CSCs - in solid organs, the aerodigestive tract (M.Alison), breast (B.Groner, DE), and also in haematological malignancies (H.E. Johnsen, DK).
  Speakers will provide an overview of current data, address the many unresolved questions as well as explore new therapies based on targeting the apparent radio- and chemoresistance of CSCs. Finally, they will signpost the necessary next steps in cancer stem cell research and the consequent potential for future therapies.

• Oncogenes revisited Wednesday 23 September 2009, 14:45 - 16:45
  Presenting on the Epidermal growth factor system of ligands and receptors in cancer (Chair, W. Gullick, UK), RAS in cellular transformation and senescence (D. Tuveson, UK), the Role of mTOR in cancer (S. Faivre, FR), and P53: balancing tumour suppression and implications for the clinic (V. Rotter, IL) this Symposium will provide participants with an up-to-the-minute review of the latest research as well as underpin just how many unresolved questions remain in cancer biology towards more targeted, personalised therapy for cancer patients.

• Management and interpretation of novel toxicities of molecular targeted therapies Thursday 24 September 2009, 09:00 - 11:00
  This session chaired by C. Twelves, UK, will explore the new challenges in identifying and treating a new spectrum of toxicities including Skin toxicities of targeted therapies (S. Tejpar, B), Renal toxicities (J. Carles, ES), the Cardiovascular toxicity of molecularly targeted agents (L.L. Siu, CA), and
Gastrointestinal toxicities of novel agents in cancer therapy (G. Perlemuter, FR).

Now that patients are being exposed to new molecular targeted drugs with an entirely different spectrum of toxicities affecting the kidney, cardiovascular system, skin and gastrointestinal tract, the necessity of preventing toxicities where possible as well as recognising and treating them when they arise is paramount. Within this context, the session will cover the progress, the current challenges and necessary next steps towards ensuring patients gain optimal benefit from such novel targeted therapies.

Please note: ECCO 15 - ESMO 34 Educational Symposia will be web captured, converted within the e-learning setting (including downloadable reading materials, manuscripts, powerpoint slides etc. online), ACOE accredited (Accreditation Council of Oncology in Europe) and awarded the corresponding number of CME credit points.

To download the ECCO 15 - ESMO 34 Advance Programme* click here.

* The Advance Programme online will be fully updated this coming August!

Teaching Lectures

The ECCO 15 - ESMO 34 range of topical Teaching Lectures will take place from 08:00 - 08:45 from Monday 21 September - Thursday 24 September.

Participants can enjoy and learn from state-of-the-art lectures given by leading experts within the field, followed by interactive debate and open discussion. Covering a wide variety of topics promising cross discipline appeal, here are just some of the many Teaching Lecture Highlights:

Monday 21 September, 08:00 - 08:45

Track: Genitourinary Malignancies - Prostate Cancer

Title: New agents for metastatic prostate cancer

Speaker: K. Fizazi (France)

Tuesday 22 September, 08:00 - 08:45

Track: Gastrointestinal Malignancies - Colorectal Cancer

Title: The KRAS story and beyond

Speaker: P.G. Johnston (Ireland)

Wednesday 23 September, 08:00 - 08:45

Track: Basic Science
Title: Chromatin remodelling and cancer

Speaker: Z. Herceg (France)
Thursday 24 September, 08:00 - 08:45

Track: Gynaecological Cancer

Title: Overview of cervical vaccination

Speaker: E. Joura (Austria)

To view the full Teaching Lecture programme and download the ECCO 15 - ESMO 34 Advance Programme* click here.

*The Advance Programme online will be fully updated this coming August!

EACR Special Conference on Inflammation and Cancer

A unique opportunity to meet the leaders in the inflammation and cancer field!

The EACR Special Conference on Inflammation and Cancer will be the first meeting of its kind in Europe to bring an important and rapidly expanding area of cancer research to many cancer researchers in the EC community.

Running over one and a half days immediately after the ECCO 15 - ESMO 34 Congress from Thursday 24 September (13:45 - 20:00) to Friday 25 September (08:30 - 17:30), Congress Chair, Claire Lewis, outlines why you should add this special conference to your agenda:

It is now well established that inflammatory mechanisms drive tumour initiation, development and metastasis. This exciting meeting will outline the way in which various inflammatory cells and the factors they produce regulate key steps in tumour progression.

Keynote talks will be delivered by Drs Lisa Coussens (San Francisco, USA) and Alberto Mantovani (Milan, Italy) followed by leading specialists in the field from the USA and Europe. Symposium topics will include mouse models of tumour inflammation, the role of individual inflammatory cells/mediators in tumour angiogenesis and immunosuppression, and how to target these in new therapeutic approaches. As such, this Special Conference represents a must-attend for basic, translational and clinical scientists alike.

To view the latest Scientific Programme, outstanding panel of Faculty members and to secure your place by registering today click here.
Latest News from the EACR:

It has just been announced that Fabrizio d’Adda di Fagagna, Principal Investigator at the FIRC Institute of Molecular Oncology, Milan, Italy, has been selected as the winner of the EACR Young Cancer Researcher Award for 2009.

Introduced by Anne-Lise Børresen-Dale (EACR President and Session Chair), the Award Lecture on Chromatin modulates DNA damage response activation in oncogene-expressing cells will take place during EACR Special Session, 22 September, 09:00 - 11:00, in the Roof Garden Room.

Professor Børresen-Dale is delighted to be joined at the Special Session by Carlos Caldas (UK), Ole W. Peterson (DK) and Marco A Pierotti (IT), and to be introducing their talks at one of the many exciting sessions during the Congress.

Late-Breaking Abstracts

The ECCO 15 - ESMO 34 Scientific Committee strongly encourages the submission of abstracts on Phase I, Phase II and large phase III trials coming to an end or having new data available by mid 2009. Late-breaking abstracts should highlight novel and practice changing studies.

Our Late-Breaking Call will run from 22 July - 05 August 2009 to capture abstracts with ground-breaking and unique data that would not otherwise have been presented at the conference.

Examples of suitable late-breaking abstracts include: the results of a practice-changing prospective Phase III clinical trial, a Phase II study showing anti-tumour activity in a novel context, an early clinical trial with novel proof-of-principle data, or the demonstration of novel cancer biology with therapeutic implications.

To view our late-breaking abstract submission policy and regulations click here.

As a demonstration of your commitment to advancing European cancer therapeutics and prevention, we look forward to receiving your exciting data!
pharmaceutical and technical industries ultimately contributes to improved understanding, management and care of patients with cancer.

The ECCO 15 - ESMO 34 series of Industry Sponsored Satellite Symposia facilitate critical insight, interactive discussion and devoted questioning.

**ECCO 15 - ESMO 34 Satellite Symposia at a Glance:**

**Sunday 20 September**
- **Prime Oncology**: Breast Cancer: Evaluating Current Standards and Formulating Strategies for the Next Decade.
- **Lilly Oncology**: Changing the treatment paradigm in advanced NSCLC: myth or reality?
- **Novartis Oncology**: Understanding Data...Formulating Answers: Strategies for Treating Solid Tumors
- **Hospira**: Erythropoietins in Oncology: An interactive review of current thinking and new options
- **Wyeth Pharmaceuticals**: Therapy to clinical practice: not all mRCC patients are the same! A Patient Case Discussion Symposium
- **Astra Zeneca**: AstraZeneca targeted therapies in NSCLC. A voyage of discovery: gefitinib and beyond
- **Pfizer Oncology**: Pfizer-sponsored Renal Cell Carcinoma Satellite Symposium
- **F. Hoffmann-La Roche Ltd**: Innovation: the key to optimal cancer care
- **Novartis Oncology**: New Approaches in GIST Management - Clinical
<table>
<thead>
<tr>
<th>Company</th>
<th>Title of Symposium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Oncology</td>
<td>Tailoring Breast Cancer Treatments with Targeted Therapies. A Patient Case Discussion Symposium</td>
</tr>
<tr>
<td>F. Hoffmann-La Roche Ltd</td>
<td>Breast Cancer Treatment on the Cutting Edge: Understanding the Options</td>
</tr>
<tr>
<td>Bayer Healthcare Pharmaceuticals</td>
<td>New Paradigms in kidney and liver cancer management</td>
</tr>
<tr>
<td>Schering Plough</td>
<td>Current Trends in the Treatment of CNS Malignancies</td>
</tr>
<tr>
<td>GSK Oncology</td>
<td>‘New Therapeutic Approaches in Resected NSCLC’ - How to better select patients and focus the therapy</td>
</tr>
</tbody>
</table>

Monday 21 September 2009
<table>
<thead>
<tr>
<th>Company</th>
<th>Title of Symposium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merck Serono</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>Pfizer Oncology</td>
<td>Maximising patient outcomes with targeted agents in mRCC: Current and future strategies</td>
</tr>
<tr>
<td>Amgen Europe GmbH</td>
<td>The bone and the marrow. Ispa scientia potestas est</td>
</tr>
<tr>
<td>Schering Plough</td>
<td>Benchmark Studies Advancing the Treatment of Ovarian Cancer</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>New Perspectives to Address The Challenge of Castration-Resistant Prostate Cancer</td>
</tr>
<tr>
<td>Pharmamar SA</td>
<td>Stepping into the future… Broadening the role of trabectedin in cancer therapy</td>
</tr>
<tr>
<td>Merck Serono</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>Amgen Europe GmbH</td>
<td>Panitumumab, a Fully Human Anti--EGFR MAb Under Investigation With Chemotherapy In MCRC</td>
</tr>
<tr>
<td>Vifor Pharma</td>
<td>Managing the anemic cancer patient - what is the role of intravenous iron?</td>
</tr>
<tr>
<td>Abraxis Bioscience</td>
<td>From Translational Science to Clinical Practice: Advancing the Treatment of Metastatic Breast Cancer with ABRAXANE</td>
</tr>
</tbody>
</table>
Please bookmark: [www.ecco-org.eu](http://www.ecco-org.eu) (Select ‘Congresses and conferences’ > ‘ECCO 15 - ESMO 34’) for forthcoming announcements and more detailed information.